**Introduction:** Individuals with chronic kidney diseases (CKD) are at risk of developing gout due to hyperuricemia due to renal impairment and other risk factors like concomitant diuretic therapy, hypertension etc. Patients with advanced CKD have altered bone metabolism like hyperparathyroidism and can develop other musculoskeletal problems. Renal transplant patients with graft dysfunction are a special group of patients with CKD. In addition to problems of CKD, they are on immunosuppressive therapy which can make disease management of gout and other musculoskeletal problems challenging. We would like to discuss our patient with chronic renal graft rejection who had been treated for recurrent gout episodes affecting big toe MTP joint and presented with an acute hot right knee joint.

**Case description:** Our 30-year-old male patient had a live related donor renal transplant in 2009 for CKD secondary to childhood Henoch-Schonlein Purpura. He had acute graft rejection 4 days post-transplant and had continued to have progressive fall in eGFR . He was being routinely managed by the renal team. His list of clinical problems included systemic hypertension, secondary hyperparathyroidism and recurrent gout. His regular medications included Mycophenolate, Tacrolimus, Sodium bicarbonate, Alfacalciferol, Cinacalcet, Omeprazole, Doxazosin, Tramadol, Ramipril, Bisoprolol, Amlodipine, Darbepoetin and Sevelamar carbonate. He was also on allopurinol 100mg daily and used Colchicine 500mcg3-4 times a day during episode of acute gout. In early May 2017, he presented to his GP with acutely painful and swollen right knee joint and was unable to weight bear. His GP decided to treat him with Colchicine in view of suspected gout. The patient had did not respond to Colchicine as expected and returned to GP few days later. On 19th May 2017, GP aspirated the right knee and sent the fluid for analysis and injected it with corticosteroids with limited symptom relief. He was reviewed by renal team on 8th June 2017 who reviewed the results of synovial fluid analysis which had identified calcium pyrophosphate crystals, few ragocytes, no uric acid crystals and cultures were negative. He was prescribed Prednisolone 30mg daily to which he responded well. He was able to weight bear and was referred to rheumatology for assessment. He was assessed in rheumatology clinic on 28th June 2017. Patient was well and there was no right knee joint effusion or inflammation. Other peripheral joints were unremarkable. There were identifiable tophi and the patient was systemically well. Blood investigations available in clinic were- eGFR- 18ml/min. creatinine 356µmol/l, corrected calcium 2.11mmol/l, PTH 9.8 pmol/l, normal sodium nad potassium, Vitamin d 50.6 nmol/l. His eGFR had been stable for preceding 12 months. However, his corrected calcium which was normal till 19th April 2017, had dropped to corrected calcium of 2.05mmol/l and had stayed low. Blood tests on 28th June 2017, showed CRP \< 4.0, urate 659µmol/l, serum magnesium 0.41 mmol/l and corrected calcium 2.01 mmol/l. His tacrolimus levels were 7.4 on 8th June 2017. This gentleman had hypocalcaemia (new finding) and had also been identified to have hypomagnesemia. We believe the episode of acute pseudogout is related to his metabolic derangements of hypocalcaemia and hypomagnesemia. Tacrolimus can cause hypomagnesemia and it needs correcting in order to resolve the hypocalcaemia. This gentleman has been commenced on Magnesium aspartate replacement. He continues to feel well and is off his prednisolone when last assessed on 13th July 2017

**Discussion:** Our patient had symptoms compatible with gout and had previously responded well to colchicine. Our patient gave clues in history that last episode behaved differently. Primary care physician took that on board and did the needful. This case demonstrates the need for crystallography and it should be done if possible. As secondary care physician it is important to evaluate for causative factors and not merely accept the diagnosis. History and biochemistry provided the missing pieces establish a unifying diagnosis. CPPD is rare in patients under the age of 60. Causes include hypophosphatasia, hyperparathyroidism, hemochromatosis, Gitelman's syndrome and hypomagnesaemia. These conditions highlight the interactions between electrolytes and calcium pyrophosphate crystal production. Our patient had both hypocalcaemia and hypomagnesaemia. Hypomagnesaemia causes negative feedback on parathyroid hormone (PTH) release and encourages exchange of calcium for magnesium in the bones. Although uncommon, hypocalcaemia can cause acute CPPD. This is well recognised post parathyroidectomy. Our patient became hypocalcaemic nearer the onset of acute pseudogout. Tacrolimus is associated with a high fractional renal excretion of magnesium. When this is combined with pre-existing renal disease, patients are at risk of hypomagnesemia. Magnesium affects pyrophosphatase enzyme activity which breaks down inorganic pyrophosphate. Hypomagnesemia increases inorganic pyrophosphate load. Risk of CPPD flare is further increased by history of gout. Up to 5% of patients with gout have CPPD in their synovial fluid. Joint aspiration excluded septic arthritis and confirmed acute pseudogout in our patient. Having identified pseudogout we were then able to look for an underlying cause and deal with both pseudogout and gout

**Key learning points:** People under the age of 60 should be fully investigated for pathological precipitants of acute CPPD. Hypocalcaemia and hypomagnesaemia is an important cause of CPPD with a well described pathophysiology. Correction of calcium and magnesium may prevent recurrent episodes of acute pseudogout. We should be aware of drugs that can precipitate electrolyte disturbances and present with rheumatological problems. The role of joint aspiration cannot be overemphasised and our case also lends further support to caveat.
